导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 12.24% | 575/4773 |
| 近一周 | -3.88% | 4667/5462 |
| 近一月 | -9.22% | 4636/5421 |
| 近一季 | -13.03% | 3930/5209 |
| 近半年 | 10.56% | 464/4920 |
| 近一年 | 15.05% | 702/4366 |
| 近两年 | 168.76% | 123/2954 |
| 近三年 | 122.40% | 58/2253 |
| 成立以来 | 44.74% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.12% 3529/4961 |
53.25% 522/5312 |
- - |
- - |
| 2025 | 69.42% 135/4813 |
5.53% 766/3635 |
2.40% 1595/4076 |
63.83% 56/4524 |
-4.30% 3434/4813 |
| 2024 | 18.96% 568/3463 |
-1.02% 1167/2808 |
-3.67% 1407/3014 |
15.36% 1738/3129 |
8.15% 421/3463 |
| 2023 | 8.68% 123/2656 |
37.55% 41/2280 |
-2.30% 579/2385 |
-15.87% 2237/2515 |
-3.87% 812/2655 |
| 2022 | -35.57% 1728/2207 |
-22.78% 1714/1919 |
-2.97% 1794/2016 |
-19.19% 1761/2113 |
6.41% 365/2208 |
| 2021 | 4.93% 560/1822 |
-6.71% 1032/1255 |
15.23% 234/1330 |
-10.07% 1208/1466 |
8.54% 149/1822 |
| 2020 | - - |
- - |
- - |
-4.38% 1104/1164 |
-1.14% 1093/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华富中证人工智能产业ETF联接C VS. 长安沪深300非周期A(740101) |